1. Home
  2. TAK
  3. TAK News

Latest Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of) (TAK) News on January 19, 2025

Japanese Stocks Are in the Spotlight Again. Hopes Are High for 2025.
TAK

Barrons.com

16 days ago

Japanese Stocks Are in the Spotlight Again. Hopes Are High for 2025.

TAK

MT Newswires

22 days ago

Sector Update: Health Care Stocks Mixed Pre-Bell Friday

Takeda's HYQVIA Approved in Japan To Treat Immunodeficiency
TAK

Benzinga

22 days ago

Takeda's HYQVIA Approved in Japan To Treat Immunodeficiency

TAK

MT Newswires

23 days ago

Takeda Pharmaceutical's Hyqvia Approved in Japan for Patients With Immune Disorders

Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
TAK

Business Wire

23 days ago

Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Takeda Sponsors MILESTONE Canada Advanced Inflammatory Bowel Disease (IBD) Fellowship Initiative
TAK

CNW Group

a month ago

Takeda Sponsors MILESTONE Canada Advanced Inflammatory Bowel Disease (IBD) Fellowship Initiative

Takeda Announces Subsidiary Liquidation and Merger Completion
TAK

TipRanks

a month ago

Takeda Announces Subsidiary Liquidation and Merger Completion

TAK

MT Newswires

a month ago

Hutchmed to Receive $10 Million Milestone Payment Through Takeda

HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)
TAK

GlobeNewswire

a month ago

HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)

Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas
TAK

Business Wire

a month ago

Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas

Novavax sells Czech plant to Novo; Relay licenses out a cancer drug
TAK

BioPharma Dive

a month ago

Novavax sells Czech plant to Novo; Relay licenses out a cancer drug

Takeda licensed for anaemia therapy by Keros Therapeutics
TAK

Pharmaceutical Technology

a month ago

Takeda licensed for anaemia therapy by Keros Therapeutics

Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst
TAK

Benzinga

2 months ago

Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst

TAK

MT Newswires

2 months ago

Keros Therapeutics Enters Global Development, License Deal with Takeda Pharmaceutical for Elritercept

Keros Therapeutics Announces Global License Agreement with Takeda to Advance Elritercept
TAK

GlobeNewswire

2 months ago

Keros Therapeutics Announces Global License Agreement with Takeda to Advance Elritercept

Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics
TAK

Business Wire

2 months ago

Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics

Takeda’s Strong FY2024 H1 Boosts Full-Year Outlook
TAK

TipRanks

2 months ago

Takeda’s Strong FY2024 H1 Boosts Full-Year Outlook

Why Takeda (TAK) Is One of the Most Profitable Pharmaceutical Stocks Right Now?
TAK

Insider Monkey

2 months ago

Why Takeda (TAK) Is One of the Most Profitable Pharmaceutical Stocks Right Now?

Takeda Canada co-sponsors grant to boost IBD clinical research
TAK

Clinical Trials Arena

2 months ago

Takeda Canada co-sponsors grant to boost IBD clinical research

TAK

MT Newswires

2 months ago

Hutchmed to Receive Milestone Payment for Takeda's Fruzaqla Launch in Japan

HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan
TAK

GlobeNewswire

2 months ago

HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan

Takeda and Alloy Therapeutics partner to make off-the-shelf CAR-T therapies
TAK

Pharmaceutical Technology

2 months ago

Takeda and Alloy Therapeutics partner to make off-the-shelf CAR-T therapies

Why this major drugmaker no longer has an ‘IT department’
TAK

Fortune

2 months ago

Why this major drugmaker no longer has an ‘IT department’

New Survey Data Highlights the Importance of Prioritizing Mental Health for Canadians Living with IBD
TAK

CNW Group

2 months ago

New Survey Data Highlights the Importance of Prioritizing Mental Health for Canadians Living with IBD

TAK

MT Newswires

3 months ago

HUTCHMED Earns $20 Million Milestone Payment After Takeda Reaches Over $200 Million in Fruquintinib Sales

TAK

MT Newswires

3 months ago

Takeda Pharmaceutical's Fiscal Q2 Core Earnings, Revenue Increase; Fiscal-Year Outlook Raised

HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda
TAK

GlobeNewswire

3 months ago

HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda

Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook
TAK

Business Wire

3 months ago

Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook

What To Expect From Takeda Pharmaceutical Co Ltd (TSE:4502) Q2 2025 Earnings
TAK

GuruFocus.com

3 months ago

What To Expect From Takeda Pharmaceutical Co Ltd (TSE:4502) Q2 2025 Earnings

Takeda and BMC partner to decarbonise US healthcare sector
TAK

Pharmaceutical Technology

3 months ago

Takeda and BMC partner to decarbonise US healthcare sector

TAK

MT Newswires

3 months ago

Takeda Pharmaceutical, Boston Medical Center Team Up for Decarbonization Project

Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem
TAK

Business Wire

3 months ago

Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem

TAK

Leasing Life

3 months ago

Deko and Shire Leasing partner to offer B2B leasing at checkout

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside
TAK

Benzinga

3 months ago

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside

Strategic Moves in the Japanese Market: T. Rowe Price Japan Fund's Focus on Takeda Pharmaceutical
TAK

GuruFocus.com

3 months ago

Strategic Moves in the Japanese Market: T. Rowe Price Japan Fund's Focus on Takeda Pharmaceutical

WAVE Life Sciences Ltd (WVE) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Rising ...
TAK

GuruFocus.com

3 months ago

WAVE Life Sciences Ltd (WVE) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Rising ...

TAK

MT Newswires

3 months ago

Takeda Forms Joint Venture With Astellas, Sumitomo Mitsui to Develop Early-Drug Discovery Programs in Japan

TAK or CTLT: Which Is the Better Value Stock Right Now?
TAK

Zacks

4 months ago

TAK or CTLT: Which Is the Better Value Stock Right Now?

Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?
TAK

Zacks

4 months ago

Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?

Tempus Stock Up Following Collaboration Expansion in Oncology R&D
TAK

Zacks

4 months ago

Tempus Stock Up Following Collaboration Expansion in Oncology R&D

How Many Stocks Should You Own?
TAK

Zacks

4 months ago

How Many Stocks Should You Own?

Tempus AI expands oncology collaboration with Takeda
TAK

Pharmaceutical Technology

4 months ago

Tempus AI expands oncology collaboration with Takeda

TAK

MT Newswires

4 months ago

Tempus AI Expands Takeda Partnership to Support Cancer Drug Research

TAK

MT Newswires

4 months ago

Alvotech Starts Confirmatory Study for Biosimilar Candidate to Entyvio

The Zacks Analyst Blog Highlights Takeda Pharma, Naspers and Packaging Corp. of America
TAK

Zacks

4 months ago

The Zacks Analyst Blog Highlights Takeda Pharma, Naspers and Packaging Corp. of America

Takeda’s FRUZAQLA approved in Japan for advanced colorectal cancer
TAK

Pharmaceutical Technology

4 months ago

Takeda’s FRUZAQLA approved in Japan for advanced colorectal cancer

TAK

MT Newswires

4 months ago

Takeda Pharmaceutical Says Colorectal Cancer Drug Received Marketing Approval in Japan

Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer
TAK

Business Wire

4 months ago

Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer

HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda
TAK

GlobeNewswire

4 months ago

HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda

MHRA approves Takeda’s fruquintinib for metastatic colorectal cancer
TAK

Pharmaceutical Technology

4 months ago

MHRA approves Takeda’s fruquintinib for metastatic colorectal cancer

Takeda Pharmaceutical Company Limited (TAK): Hedge Funds Are Bullish On This Japanese Stock Now
TAK

Insider Monkey

4 months ago

Takeda Pharmaceutical Company Limited (TAK): Hedge Funds Are Bullish On This Japanese Stock Now

Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024
TAK

Business Wire

4 months ago

Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024

Lupin and Takeda to commercialise Vonoprazan in India
TAK

Pharmaceutical Technology

4 months ago

Lupin and Takeda to commercialise Vonoprazan in India

Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries
TAK

Business Wire

4 months ago

Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries

TAK vs. STVN: Which Stock Is the Better Value Option?
TAK

Zacks

4 months ago

TAK vs. STVN: Which Stock Is the Better Value Option?

Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now?
TAK

Zacks

4 months ago

Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now?

Vatroslav Mateljic Appointed General Manager of Takeda Canada
TAK

CNW Group

4 months ago

Vatroslav Mateljic Appointed General Manager of Takeda Canada

Buyout Firm GTCR Is in Advanced Talks to Acquire German Drugmaker Stada
TAK

Bloomberg

4 months ago

Buyout Firm GTCR Is in Advanced Talks to Acquire German Drugmaker Stada

Investors are waking up to Centessa’s sleepiness drug
TAK

BioPharma Dive

4 months ago

Investors are waking up to Centessa’s sleepiness drug

Takeda Pharmaceutical Company Limited (TAK): A Cheap Pharmaceutical Stock to Buy According to Short Sellers
TAK

Insider Monkey

5 months ago

Takeda Pharmaceutical Company Limited (TAK): A Cheap Pharmaceutical Stock to Buy According to Short Sellers

Takeda’s ADZYNMA gains EU approval for cTTP treatment
TAK

Pharmaceutical Technology

5 months ago

Takeda’s ADZYNMA gains EU approval for cTTP treatment

Why Is Japanese Drugmaker Takeda Pharmaceutical Stock Trading Higher On Wednesday?
TAK

Benzinga

5 months ago

Why Is Japanese Drugmaker Takeda Pharmaceutical Stock Trading Higher On Wednesday?

TAK

MT Newswires

5 months ago

Takeda Wins European Commission's Approval for Adzynma to Treat Blood Clotting Disorder

Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
TAK

Business Wire

5 months ago

Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Japan Fund That Beat 92% of Peers in 2024 Touts Seven & I, Orix
TAK

Bloomberg

5 months ago

Japan Fund That Beat 92% of Peers in 2024 Touts Seven & I, Orix

Japan’s Selloff Sank Global Markets. Why This Fund Manager Is Still Bullish.
TAK

Barrons.com

5 months ago

Japan’s Selloff Sank Global Markets. Why This Fund Manager Is Still Bullish.

TAK

MT Newswires

6 months ago

Update: Market Chatter: Takeda Pharmaceutical to Eliminate 1,000 US Jobs

TAK

MT Newswires

6 months ago

Market Chatter: Takeda Pharmaceutical to Eliminate 1,000 US Jobs

Takeda’s revenue climbs by 14.1% in Q1 FY2024
TAK

Pharmaceutical Technology

6 months ago

Takeda’s revenue climbs by 14.1% in Q1 FY2024

TAK

MT Newswires

6 months ago

Sector Update: Health Care Stocks Flat to Lower Premarket Wednesday

TAK

MT Newswires

6 months ago

Takeda Pharmaceutical Fiscal Q1 Earnings, Revenue Increase; Reaffirms Fiscal 2024 Guidance

Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline
TAK

Business Wire

6 months ago

Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline

TAK

MT Newswires

6 months ago

Dr. Reddy's Laboratories to Market Takeda's Acid-Reflux Medication in India

Shire Leasing accredited to deliver Growth Guarantee Scheme
TAK

Leasing Life

6 months ago

Shire Leasing accredited to deliver Growth Guarantee Scheme

Polpharma looks to challenge Takeda’s Entyvio in IBD
TAK

Pharmaceutical Technology

6 months ago

Polpharma looks to challenge Takeda’s Entyvio in IBD

TAK

MT Newswires

7 months ago

Bloomberg Video: Takeda To Keep Pushing for China Biotech Partnership

Takeda Announces New Assignments of Directors
TAK

Business Wire

7 months ago

Takeda Announces New Assignments of Directors

FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder
TAK

Zacks

7 months ago

FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder

Takeda reports positive data from Phase IIb trial of ITP treatment
TAK

Clinical Trials Arena

7 months ago

Takeda reports positive data from Phase IIb trial of ITP treatment

EC approves Takeda’s Fruzaqla for metastatic colorectal cancer
TAK

Pharmaceutical Technology

7 months ago

EC approves Takeda’s Fruzaqla for metastatic colorectal cancer

TAK

MT Newswires

7 months ago

Takeda's Organ Transplant Infection Treatment Approved by Japan Regulators

Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies
TAK

Business Wire

7 months ago

Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies

Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
TAK

Business Wire

7 months ago

Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia

TAK

MT Newswires

7 months ago

Takeda Secures European Commission's Approval for Colorectal Cancer Drug Fruzaqla

Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer
TAK

Business Wire

7 months ago

Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer

HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
TAK

GlobeNewswire

7 months ago

HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda

Takeda's HyQvia® Approved as Replacement Therapy for Primary Humoral Immunodeficiency and Secondary Humoral Immunodeficiency in Pediatric Patients 2 years of Age and Older
TAK

CNW Group

7 months ago

Takeda's HyQvia® Approved as Replacement Therapy for Primary Humoral Immunodeficiency and Secondary Humoral Immunodeficiency in Pediatric Patients 2 years of Age and Older

Takeda reports long-term data from Phase III CIDP treatment trial
TAK

Clinical Trials Arena

7 months ago

Takeda reports long-term data from Phase III CIDP treatment trial

OVID Slumps 76% on Epilepsy Drug Failing Two Pivotal Studies
TAK

Zacks

7 months ago

OVID Slumps 76% on Epilepsy Drug Failing Two Pivotal Studies

TAK

MT Newswires

7 months ago

Takeda Pharmaceutical Says Results of Phase 3 Trial Support Use of Hyqvia as Maintenance Treatment for CIDP

Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
TAK

Business Wire

7 months ago

Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting

Takeda’s epilepsy drug misses the mark in two Phase III trials
TAK

Clinical Trials Arena

7 months ago

Takeda’s epilepsy drug misses the mark in two Phase III trials

TAK

MT Newswires

7 months ago

Ovid Seeks Distance From Epilepsy Drug After Takeda Reports Phase 3 Endpoints Missed -- Pre-Bell Shares Fall

Takeda drug for rare types of epilepsy misses goal in late-stage trial
TAK

BioPharma Dive

7 months ago

Takeda drug for rare types of epilepsy misses goal in late-stage trial

TAK

MT Newswires

7 months ago

Takeda Says Phase 3 Soticlestat Trials in Dravet, Lennox-Gastaut Syndromes Missed Primary Endpoints

Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome
TAK

Business Wire

7 months ago

Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome

Takeda signs option agreement with Ascentage for CML drug
TAK

Pharmaceutical Technology

7 months ago

Takeda signs option agreement with Ascentage for CML drug

TAK

MT Newswires

7 months ago

Takeda Signs Option Agreement with Ascentage to License Leukemia Drug

Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
TAK

Business Wire

7 months ago

Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)

Takeda circles a leukemia drug; J.P. Morgan moves into biotech investing
TAK

BioPharma Dive

7 months ago

Takeda circles a leukemia drug; J.P. Morgan moves into biotech investing

Share on Social Networks: